Salivary gland disorder
diseaseOn this page
Also known as disease of saliva-secreting glanddisease or disorder of saliva-secreting glanddisorder of saliva-secreting glandnon-neoplastic salivary gland diseasesaliva-secreting gland diseasesaliva-secreting gland disease or disordersalivary gland disease
Summary
Salivary gland disorder (MONDO:0001142) is a disease (an umbrella term covering 9 Mondo subtypes) with 3 GWAS associations across 23 studies and 14 clinical trials. Top therapeutic interventions include ciprofloxacin, prasterone, and honey. A subtype of mouth disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 9 Mondo subtypes
- GWAS associations: 3
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | salivary gland disorder |
| Mondo ID | MONDO:0001142 |
| EFO | EFO:0008581 |
| MeSH | D012466 |
| DOID | DOID:10854 |
| ICD-11 | 1432273670 |
| NCIT | C26879 |
| SNOMED CT | 10890000 |
| UMLS | C0149772 |
| MedGen | 892384 |
| Anatomy (UBERON) | UBERON:0001044 |
| Is cancer (heuristic) | no |
Also known as: disease of saliva-secreting gland · disease or disorder of saliva-secreting gland · disorder of saliva-secreting gland · non-neoplastic salivary gland disease · saliva-secreting gland disease · saliva-secreting gland disease or disorder · salivary gland disease · salivary gland disorder
Data availability: 3 GWAS associations (23 studies).
Disease family
This is a subtype of mouth disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › mouth disorder › salivary gland disorder
Related subtypes (26): uvulitis, adenoid hypertrophy, oral hairy leukoplakia, tongue disorder, alveolar periostitis, lip disorder, oral Crohn disease, maxillary sinusitis, oral candidiasis, oral tuberculosis, Ludwig’s angina, maxillary sinus cholesteatoma, burning mouth syndrome, oral leukoedema, tooth disorder, commissural lip fistula, oral submucous fibrosis, florid cemento-osseous dysplasia, oral cavity neoplasm, neoplasm of floor of mouth, polyp of maxillary sinus, neoplasm of jaw, osteoradionecrosis of the mandible, odontoma, lichen planus, oral, mouth mucosa disorder
Subtypes (9): submandibular gland disorder, benign lymphoepithelial lesion of salivary gland, mucocele of salivary gland, parotid disorder, necrotizing sialometaplasia, sialadenitis, sialolithiasis, Sjogren syndrome, tumor of salivary gland
Genetics & variants
GWAS landscape
3 GWAS associations across 23 studies. Top hits map to 3 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs1647960 | 3e-10 | RN7SL167P - NTM | ? | |
| rs61156710 | 4e-09 | SGCD | ? | |
| rs117032761 | 5e-08 | KBTBD11-OT1, ARHGEF10 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478297 | Verma A | 2024 | 9,270 | 428,988 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478302 | Verma A | 2024 | 6,556 | 434,802 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90473763 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 3,463 | 454,977 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90478296 | Verma A | 2024 | 2,550 | 115,410 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480861 | Verma A | 2024 | 2,550 | 115,410 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478301 | Verma A | 2024 | 1,657 | 117,317 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480840 | Verma A | 2024 | 1,657 | 117,317 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90080177 | Backman JD | 2021 | 1,546 | 384,408 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084163 | Backman JD | 2021 | 1,546 | 384,408 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90478295 | Verma A | 2024 | 1,388 | 56,624 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 3 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 2 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 2 |
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs1647960 | 11 | 131051857 | G>A,T | 0.05 | intergenic_variant | RN7SL167P - NTM | 3e-10 | Tier 4: intronic/intergenic |
| rs61156710 | 5 | 156486436 | C>T | intron_variant | SGCD | 4e-09 | Tier 4: intronic/intergenic | |
| rs117032761 | 8 | 1898412 | C>A,G | intron_variant | KBTBD11-OT1, ARHGEF10 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 10 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02068846 | PHASE3 | COMPLETED | BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent |
| NCT00001598 | PHASE2 | COMPLETED | DHEA Treatment for Sjogren’s Syndrome |
| NCT01762514 | PHASE2 | UNKNOWN | A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens |
| NCT03874572 | PHASE1 | UNKNOWN | Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth |
| NCT02327884 | Not specified | RECRUITING | Characterization of Diseases With Salivary Gland Involvement |
| NCT00001390 | Not specified | COMPLETED | Salivary Evaluation in Healthy Volunteers |
| NCT00001852 | Not specified | COMPLETED | Natural History of Salivary Gland Dysfunction and Sjogren’s Syndrome |
| NCT01915966 | Not specified | COMPLETED | Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients |
| NCT03746730 | Not specified | UNKNOWN | Role of US,Doppler in Major Salivary Gland Diseases |
| NCT03893812 | Not specified | UNKNOWN | Color Doppler and Mri Diffusion in Major Salivary Gland Masses |
| NCT04507646 | Not specified | COMPLETED | The Effectiveness of Auricular Acupuncture on Improving Secretion of Saliva Among Institutional Older Population |
| NCT05151029 | Not specified | UNKNOWN | Elastography in the Evaluation of Major Salivary Gland Lesions |
| NCT05346341 | Not specified | COMPLETED | Evaluation of the Effect of Minimally Invasive Procedures Used in Management of Salivary Ductal Pathologies on Patients’ Symptomatology and Gland Function |
| NCT06240806 | Not specified | COMPLETED | Efficacy of Manuka Honey Oral Rinse in Treatment of Xerostomia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CIPROFLOXACIN | 4 | 1 |
| PRASTERONE | 4 | 1 |
| HONEY | 3 | 1 |
| CHEMBL31399 | 0 | 1 |
Related Atlas pages
- Drugs: Ciprofloxacin, Prasterone, Honey